# A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric 

Source: https://onco.cc/trials/nct06008054/  
OnCo record `nct06008054` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Izalontamab brengitecan in colorectal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors is a phase 2 interventional study registered as NCT06008054 by Sichuan Baili Pharmaceutical Co., Ltd., with 376 participants planned, started 2023-11-16 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B003, BL-B01D1, PD-1 Monoclonal Antibody. Conditions listed: Esophageal Cancer, Gastric Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06008054
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 376

## Sources

- ClinicalTrials.gov NCT06008054: https://clinicaltrials.gov/study/NCT06008054

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06008054.json